TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CellSource Co., Ltd. ( (JP:4880) ) has shared an announcement.
CellSource Co., Ltd. reported a decrease in its July 2025 contract processing orders, with a significant drop in blood-derived product orders for hybrid orthopedics. Despite the decline, the company remains committed to strengthening its organizational structure and maintaining planned order volumes, while continuing initiatives with key medical institutions.
The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry, focusing on contract processing services for blood-derived and adipose-derived stem cell products. The company is listed on the Tokyo Stock Exchange and targets the medical sector, including orthopedics and cosmetics.
Average Trading Volume: 50,130
Technical Sentiment Signal: Sell
Current Market Cap: Yen13.61B
For detailed information about 4880 stock, go to TipRanks’ Stock Analysis page.